Document Detail

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
MedLine Citation:
PMID:  10543929     Owner:  NLM     Status:  MEDLINE    
CONCLUSIONS: Higher activated partial thromboplastin time levels during inogatran treatment are related to increased risk of death, myocardial infarction or refractory angina. This might, at least in part, be explained by differences in anticoagulant mechanisms between direct thrombin inhibitors and heparin, and further emphasizes the poorly defined optimal activated partial thromboplastin time range during treatment with direct thrombin inhibitors in unstable coronary artery disease.
J Oldgren; R Linder; L Grip; A Siegbahn; L Wallentin
Related Documents :
10731289 - Combination enoxaparin and abciximab therapy during percutaneous coronary intervention:...
22222229 - Dose-dependent acute effects of passive smoking on left ventricular cardiac functions i...
9597519 - Rationale and clinical evidence for the use of gp iib/iiia inhibitors in acute coronary...
17065179 - Effects of platelet glycoprotein iib/iiia receptor blockers in non-st segment elevation...
1535419 - Do the results of randomized clinical trials of cardiovascular drugs influence medical ...
19778669 - Cost effectiveness of enoxaparin in acute st-segment elevation myocardial infarction: t...
9514469 - Comparison of frequency of new coronary events in older persons with mild, moderate, an...
3958339 - Reproducibility of arrhythmia induction with intracardiac electrophysiologic testing: p...
16118069 - Apolipoprotein e polymorphism is not a predictor for repeated coronary artery bypass su...
Publication Detail:
Type:  Clinical Trial; Comment; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  20     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1999 Nov 
Date Detail:
Created Date:  2000-01-19     Completed Date:  2000-01-19     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1657-66     Citation Subset:  IM    
Copyright Information:
Copyright 1999 The European Society of Cardiology.
Department of Cardiology, Uppsala University Hospital, Uppsala.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angina, Unstable / blood,  drug therapy*,  mortality
Antithrombins / administration & dosage*,  adverse effects
Cause of Death
Coronary Disease / blood,  drug therapy*,  mortality
Dose-Response Relationship, Drug
Glycine / administration & dosage,  adverse effects,  analogs & derivatives*
Heparin / administration & dosage,  adverse effects
Infusions, Intravenous
Middle Aged
Myocardial Infarction / blood,  drug therapy*,  mortality
Partial Thromboplastin Time*
Piperidines / administration & dosage*,  adverse effects
Survival Rate
Thrombin / antagonists & inhibitors*,  metabolism
Treatment Outcome
Reg. No./Substance:
0/Antithrombins; 0/Piperidines; 428409I84L/inogatran; 56-40-6/Glycine; 9005-49-6/Heparin; EC
Comment On:
Eur Heart J. 1997 Sep;18(9):1416-25   [PMID:  9458447 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patient...
Next Document:  The impact of cachexia on cardiorespiratory reflex control in chronic heart failure.